Home › Funds › RBB FUND, INC. › F/m Emerald Life Sciences Innovation ETF
Fund family: RBB FUND, INC. · Filed by RBB FUND, INC. (CIK 831114) · SEC series S000088167
Ticker: LFSC (C000254221)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 263 with, 1 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as RBB FUND, INC.’s manager page (32,541 ballot items across 32 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | RBB FUND, INC. | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 78.6% | 257 | 93.2% | 28,258 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 11.4% | 324 |
Each ballot item this fund voted is set against the votes of the other RBB FUND, INC. funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most RBB FUND, INC. funds on 9 items (15.5% of the 58 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most RBB FUND, INC. funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| GLOBUS MEDICAL, INC. | 2026-06-03 | Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Keith W. Pfeil | Withhold | FOR — 3 of 3 RBB FUND, INC. funds | Against | Elected, 91.3% support |
| GLOBUS MEDICAL, INC. | 2026-06-03 | Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Robert Douglas | Withhold | FOR — 3 of 3 RBB FUND, INC. funds | Against | Elected, 96.9% support |
| AXSOME THERAPEUTICS, INC. | 2026-06-05 | Election of Director: 1. Mark Saad | Withhold | FOR — 3 of 4 RBB FUND, INC. funds | Against | — |
| AXSOME THERAPEUTICS, INC. | 2026-06-05 | Election of Director: 2. Susan Mahony, PhD., MBA | Withhold | FOR — 3 of 4 RBB FUND, INC. funds | Against | — |
| GUARDANT HEALTH, INC. | 2026-06-17 | Election of Class II Directors Ian Clark | Withhold | FOR — 3 of 5 RBB FUND, INC. funds | Against | — |
| GUARDANT HEALTH, INC. | 2026-06-17 | Election of Class II Directors Manuel Hidalgo Medina | Withhold | FOR — 3 of 5 RBB FUND, INC. funds | Against | — |
| BRIDGEBIO PHARMA, INC. | 2026-06-22 | Election of Director: 1. James C. Momtazee | Withhold | FOR — 3 of 5 RBB FUND, INC. funds | Against | — |
| BRIDGEBIO PHARMA, INC. | 2026-06-22 | Election of Director: 2. Frank P. McCormick, PhD | Withhold | FOR — 3 of 5 RBB FUND, INC. funds | Against | — |
| BRIDGEBIO PHARMA, INC. | 2026-06-22 | Election of Director: 3. Hannah A. Valantine, MD | Withhold | FOR — 3 of 5 RBB FUND, INC. funds | Against | — |
Download all 9 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 97.3% of this fund’s 264 such votes could be given a sector; the other 7 (2.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 249 | 1 | 0.4% |
| Technology | 8 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 164 | 0 |
| Audit-related | 37 | 0 |
| Say-on-Pay | 36 | 0 |
| Compensation | 17 | 0 |
| Capital Structure | 9 | 0 |
| Corporate Governance | 6 | 1 |
| Other | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| SPYRE THERAPEUTICS INC. | May 27, 2026 | $10M | 6 | 0 |
| TRAVERE THERAPEUTICS, INC. | May 19, 2026 | $8M | 14 | 0 |
| GUARDANT HEALTH, INC. | June 17, 2026 | $6M | 5 | 0 |
| COGENT BIOSCIENCES, INC. | June 9, 2026 | $6M | 5 | 0 |
| MIRUM PHARMACEUTICALS, INC. | June 15, 2026 | $5M | 5 | 0 |
| UNITED THERAPEUTICS CORPORATION | June 26, 2026 | $5M | 15 | 0 |
| BRIDGEBIO PHARMA, INC. | June 22, 2026 | $4M | 7 | 0 |
| ICU MEDICAL, INC. | May 13, 2026 | $4M | 13 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 13, 2026 | ICU MEDICAL, INC. | To approve, on an advisory basis, a stockholder proposal to establish a 10% stockholder special meeting right. Shareholder proposal | For | Against |
270 ballot items at 36 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, F/m Emerald Life Sciences Innovation ETF (LFSC) voted at 36 shareholder meetings of 35 companies, on 270 ballot items in all. Where management made a recommendation, the fund followed it on 99.6% of the items and voted against it 1 time. Its most frequent area of disagreement was corporate governance (1 of its votes against management). It voted on 1 shareholder proposal. It voted FOR the board's own proposals less often than RBB FUND, INC.'s funds as a whole (78.6% against 93.2%). It voted differently from most RBB FUND, INC. funds on 9 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of RBB FUND, INC.’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.